Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenkang is a traditional Chinese medicine (TCM) used for the treatment of chronic kidney disease (CKD), available in various formulations including injection (SKI), granules (SKG), and suppositories (SKS). The formula consists of several herbs, primarily rhubarb (Rheum palmatum L.), safflower (Carthamus tinctorius L.), astragalus (Astragalus mongholicus Bunge), and red sage (Salvia miltiorrhiza Bunge). [1, 3] Its therapeutic effects in CKD are attributed to its ability to reduce renal fibrosis, inflammation, and oxidative stress. [5, 6] Mechanistically, Shenkang has been shown to inhibit the renin-angiotensin system (RAS) by blocking the Wnt/β-catenin signaling pathway. [11] It also modulates other pathways, including PI3K/Akt and MAPK. [1, 5] Active components responsible for its effects include anthraquinones like rhein and emodin, as well as hydroxysafflor yellow A, tanshinol, and astragaloside IV. [5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shenkang.